---
title: "Satellos Bioscience Raises $57.2 Million Through Share and Pre-Funded Warrant Offering"
description: "Satellos Bioscience Inc. has raised approximately $57.2 million through an underwritten public offering, issuing 5,168,019 common shares at $10.10 each and pre-funded warrants at $10.09999 each. The f"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275367976.md"
published_at: "2026-02-09T22:00:18.000Z"
---

# Satellos Bioscience Raises $57.2 Million Through Share and Pre-Funded Warrant Offering

> Satellos Bioscience Inc. has raised approximately $57.2 million through an underwritten public offering, issuing 5,168,019 common shares at $10.10 each and pre-funded warrants at $10.09999 each. The funds will primarily support ongoing research and development, including advancing SAT-3247 through clinical trials and other development programs.

Satellos Bioscience Inc. has completed its previously announced underwritten public offering, which included the issuance of 5,168,019 common shares and pre-funded warrants to purchase 495,049 common shares. The common shares were sold at US$10.10 per share, while the pre-funded warrants were sold at US$10.09999 per warrant. The total gross proceeds from the offering were approximately US$57.2 million, before deducting underwriting discounts and commissions. The proceeds will primarily support ongoing research and development activities, including the advancement of SAT-3247 through clinical trials and investment in other development programs. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Satellos Bioscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260209211048) on February 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md)
- [MSLE.US - Satellos Bioscience](https://longbridge.com/en/quote/MSLE.US.md)
- [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| An Overview of Nuvation Bio's Earnings | Nuvation Bio (NYSE:NUVB) is set to announce its quarterly earnings on March 2, 2026, with analysts estimating an EPS of  | [Link](https://longbridge.com/en/news/277235801.md) |
| BUZZ-Zura Bio falls after commencing stock offering | Zura Bio's shares fell 4.8% to $6.37 after announcing a stock offering. The company plans to raise funds for working cap | [Link](https://longbridge.com/en/news/276793071.md) |
| Delcath Q4 revenue rises 37%, beats estimates | Delcath Systems reported a 37% increase in Q4 revenue, surpassing analyst expectations with $20.73 million. Despite a ne | [Link](https://longbridge.com/en/news/277046688.md) |
| Exploring Belite Bio's Earnings Expectations | Belite Bio (NASDAQ:BLTE) will report its quarterly earnings on March 2, 2026, with analysts estimating an EPS of $-0.55. | [Link](https://longbridge.com/en/news/277224746.md) |
| 10:08 ETCellipont Bioservices and Soter Bio Announce Strategic Collaboration to Support Integrated U.S. Cell Therapy Manufacturing | Cellipont Bioservices and Soter Bio have announced a strategic collaboration to enhance U.S. cell therapy manufacturing. | [Link](https://longbridge.com/en/news/276756769.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.